Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2021

View Archived Issues

Zeolitic imidazolate frameworks for sustained checkpoint inhibitor release in cancer immunotherapy

Preclinical results of an ACE2-interacting domain of SARS-CoV-2 peptide for COVID-19 treatment

Mucolipidosis type II AAV9 gene therapy demonstrates safety in wild-type mice

Interim phase I/II data show safety and systemic efficacy of RGX-121 in patients with MPS II

Sunshine Lake Pharma discovers teixobactin analogues

Preliminary phase II data for eganelisib plus nivolumab in advanced urothelial carcinoma

SIG-018 ameliorates symptoms of MPS II in preclinical models

New dihydroceramide desaturase inhibitors presented by Cincera Therapeutics

Dana-Farber Cancer Institute describes new CDK7/cyclin H inhibitors

New E-NPP 2 inhibitors identified at Boehringer Ingelheim

BeiGene patents MAP4K1 inhibitors

One-dose immunogenicity of BNT-162b2 vaccine among different groups of Israeli healthcare workers

Orchard Therapeutics reports data from trial of OTL-201 in MPS type III A

Multiorgan organoid gives developmental insights

First phase III data presented for nivolumab in patients with high-risk MIUC under radical surgery

FDA places partial clinical hold on atuzaginstat

Neuren reports phase I data on NNZ-2591 and plans to expand development into Prader-Willi syndrome

TLX-591-CDx for prostate cancer imaging receives first E.U. approval in Czech Republic

WHO lists two versions of AstraZeneca/Oxford COVID-19 vaccine for emergency use

Valbiotis gains French clearance to begin phase II study of TOTUM-070 to reduce LDL-cholesterol

InteRNA initiates first-in-human study of INT-1B3 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...